NCT00423930View on ClinicalTrials.gov

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL

bevacizumab

DRUG

cisplatin

PROCEDURE

conventional surgery

RADIATION

intensity-modulated radiation therapy

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00423930 - Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | Biotech Hunter | Biotech Hunter